Eli Lilly is reconsidering its pricing strategy for the obesity drug Zepbound after receiving criticism that its lower-priced vials offer limited patient access. Last year, the company introduced vials of the medication, which were previously sold in injectable pens, at prices $399 or $549 a month. However, experts argued that these prices remain unaffordable for many patients.
In response to concerns, Lilly CEO Dave Ricks said the company is exploring options to expand the availability of doses and lower the entry cost. Although no official announcement has been made, Ricks hinted that vials with multiple doses could become available in the future.
Currently, Lilly’s vial offering is limited to patients who pay out-of-pocket, also known as self-pay. According to Ricks, about one in three or one in four Zepbound patients use self-pay, indicating a significant category for the company.
Source: https://www.statnews.com/2025/01/15/zepbound-vials-doses-eli-lilly-dave-ricks-interview